See more : Polaris Inc. (0KJQ.L) Income Statement Analysis – Financial Results
Complete financial analysis of Carmell Therapeutics Corporation (CTCX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Carmell Therapeutics Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- GSS Infotech Limited (GSS.BO) Income Statement Analysis – Financial Results
- Tassal Group Limited (TGR.AX) Income Statement Analysis – Financial Results
- Northern Genesis Acquisition Corp. III (NGC-WT) Income Statement Analysis – Financial Results
- Fope S.p.A. (FPE.MI) Income Statement Analysis – Financial Results
- PT Fortune Mate Indonesia Tbk (FMII.JK) Income Statement Analysis – Financial Results
Carmell Therapeutics Corporation (CTCX)
About Carmell Therapeutics Corporation
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 124.79K | 242.56K | 0.00 |
| Gross Profit | -124.79K | -242.56K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.50M | 2.20M | 982.84K |
| General & Administrative | 0.00 | 3.22M | 863.33K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.60M | 3.22M | 863.33K |
| Other Expenses | 0.00 | 10.92K | 37.38K |
| Operating Expenses | 5.09M | 5.51M | 1.94M |
| Cost & Expenses | 5.22M | 5.51M | 1.94M |
| Interest Income | 0.00 | 2.25M | 8.09K |
| Interest Expense | 889.32K | 3.75M | 2.50M |
| Depreciation & Amortization | 124.79K | 242.56K | 242.12K |
| EBITDA | -15.19M | -5.25M | -1.66M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.22M | -5.51M | -1.94M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.99M | -3.54M | -4.54M |
| Income Before Tax | -16.21M | -9.05M | -6.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -760.16K | 391.20K | 2.54M |
| Net Income | -15.45M | -9.05M | -6.48M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -1.46 | -0.46 | -0.33 |
| EPS Diluted | -1.46 | -0.46 | -0.33 |
| Weighted Avg Shares Out | 11.02M | 19.77M | 19.77M |
| Weighted Avg Shares Out (Dil) | 11.02M | 19.77M | 19.77M |
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity
Best Penny Stocks To Buy? 6 To Watch Before Next Week
Source: https://incomestatements.info
Category: Stock Reports